Welcome to our dedicated page for Diamedica Therapeutics news (Ticker: DMAC), a resource for investors and traders seeking the latest updates and insights on Diamedica Therapeutics stock.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical-stage biopharmaceutical company whose news flow centers on the development of DM199, a recombinant KLK1 protein candidate for preeclampsia, fetal growth restriction and acute ischemic stroke. Company updates frequently highlight progress in its clinical trials, regulatory interactions and financing activities that support these programs.
Investors following DMAC news can expect detailed reports on the Phase 2 investigator-sponsored trial of DM199 in preeclampsia, including interim data on blood pressure reduction, uterine artery blood flow and placental transfer findings. DiaMedica also issues news about the multi-part design of this trial, expansion cohorts, and plans to evaluate DM199 in women with early-onset fetal growth restriction.
Another major news theme is the ReMEDy2 Phase 2/3 trial in acute ischemic stroke, where DiaMedica provides enrollment updates and guidance on the timing of interim analyses. Regulatory milestones, such as the in-person pre-IND meeting with the U.S. Food and Drug Administration for a planned U.S. Phase 2 preeclampsia study and related non-clinical study requirements, are also covered in company press releases.
DiaMedica’s news feed additionally includes quarterly financial results, descriptions of its cash runway in relation to planned clinical studies, private placements and at-the-market offering arrangements. Corporate developments, such as participation in healthcare investor conferences, inducement equity grants and executive appointments in clinical leadership roles, appear regularly. For readers tracking DMAC, this news page offers a consolidated view of clinical, regulatory, financial and corporate announcements related to the company’s efforts in preeclampsia, fetal growth restriction and acute ischemic stroke.
DiaMedica Therapeutics (Nasdaq: DMAC) has announced that Dr. Harry Alcorn, Chief Medical Officer, will present a research update on CKD DM199 at the 3rd Chronic Kidney Disease Drug Development summit on March 2, 2021, at 1:00 PM ET. The presentation will cover data from the CKD Phase 1b study and the design of the Phase II Redux study. The CKD3 summit is a key event for discussing innovative treatments for chronic kidney disease, bringing together industry leaders to evaluate current drug pipelines and emerging therapies.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is set to present at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The conference will be held virtually, and the recorded presentation will be accessible on the company's website starting January 11. DiaMedica focuses on creating innovative treatments for chronic kidney diseases and neurological disorders. Investors can find more information about the presentation and the company on their official website.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that enrollment in the diabetic kidney disease cohort of its Phase 2 REDUX chronic kidney disease study is complete, with all participants now on treatment. Additionally, 50% enrollment has been achieved in the IgA Nephropathy and African Americans cohorts. This study aims to assess the safety and efficacy of DM199 in approximately 90 participants across three cohorts. Positive results from earlier studies have raised expectations for topline results, anticipated in Q2 2021.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) has received regulatory feedback from the FDA regarding its product candidate DM199 for treating acute ischemic stroke (AIS). The FDA's written responses, following a Pre-IND meeting, support the proposed design of a Phase 2/3 adaptive trial with a primary endpoint based on the modified Rankin Scale at day 90. The trial aims to enroll 300-350 participants and assess DM199's safety and efficacy. DiaMedica plans to file an IND submission soon, addressing a significant treatment gap for AIS patients within a 24-hour window.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that President and CEO Rick Pauls will participate in a fireside chat and one-on-one investor meetings at the Piper Sandler 32nd Annual Virtual Growth Conference. The chat is scheduled for November 23, 2020, at 10:00 AM ET and available until December 3, 2020. One-on-one meetings can be requested through Piper Sandler on December 1, 2020. A replay of the chat will be accessible via the Investors section of DiaMedica's website.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that President and CEO Rick Pauls and CFO Scott Kellen will participate in the Craig-Hallum Alpha Select Conference on November 17, 2020. The conference will be held virtually due to social distancing measures amid the Covid-19 pandemic. Interested institutional investors should coordinate with their Craig-Hallum representative to arrange meetings. DiaMedica is focused on developing innovative treatments for chronic kidney diseases and neurological disorders.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) has provided a business update and financial results for Q3 2020. Enrollment continues in the Phase II REDUX trial for DM199, targeting chronic kidney disease (CKD), but faces challenges due to COVID-19. 49 subjects are enrolled, with expectations for rapid enrollment in Cohort III. The FDA accepted a Type B meeting request regarding DM199 for acute ischemic stroke. A $23 million public offering was completed, bolstering cash reserves to $30.6 million. R&D expenses increased to $2.2 million, while total other income decreased to $128,000.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will release its third quarter 2020 financial results after market close on November 4, 2020. A conference call to discuss these results will be held on November 5, 2020, at 7:00 AM CT. Investors can join the call via dial-in or webcast, with replay options available until November 12, 2020. DiaMedica is focused on developing treatments for chronic kidney diseases and neurological disorders.